Filing Overview
Registrant: NLS Pharmaceutics Ltd. (the filing does not identify Newcelx Ltd. as the registrant). This Form 6-K was filed by a foreign private issuer for November 2021, Report No. 3, and signed on November 23, 2021. The registrant reports under Form 20-F.
Business Context and Reporting Period
The filing reports the filing of amended and restated Articles of Association with the commercial registry of the Canton of Nidwalden, Switzerland, on November 18, 2021. The amendment primarily addresses the registrant’s share capital and authorized and conditional share capital.
Capital Structure and Other Key Metrics
- Issued share capital increased to CHF 294,970.72, represented by 14,748,536 common shares.
- Authorized share capital: CHF 63,947.58, representing 3,197,379 common shares.
- Conditional share capital for employee and advisory options: CHF 6,949.40, representing 347,470 common shares.
- Conditional share capital for shareholders’ options: CHF 105,303.36, representing 5,265,168 common shares.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or operating performance metrics.
Material Changes
The material reported change is the adoption and registration of amended and restated Articles of Association, including revised issued, authorized, and conditional share capital provisions. The filing does not provide prior-period financial information or a comparable-period analysis.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, business outlook, management discussion, risk update, contingencies, or unusual operating items are disclosed. The amended Articles are filed as Exhibit 3.1 and incorporated by reference.
Investor Verification Items
- Verify the registrant identity: the supplied metadata names Newcelx Ltd., while the filing identifies NLS Pharmaceutics Ltd.
- Confirm the effective share capital and share counts in the filed amended and restated Articles of Association.
- Assess potential dilution from the authorized and conditional share capital, including employee, advisory, and shareholder options.
- Review Exhibit 3.1 for the complete terms governing the capital structure and option-related provisions.